Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
The investigators propose a new treatment strategy of fractionated stereotactic radiosurgery
 with concurrent bevacizumab for brain metastases. This phase I dose-escalation study is to
 establish the feasibility of this strategy and find the recommended doses.
For each group (two groups according to tumor size), the design proceeds with cohorts of
 three patients, with the first cohort treated at a starting dose. If none of the three
 patients in a cohort experiences a dose-limiting toxicity (DLT), the next cohort with three
 patients will be treated at the next higher dose level. If one of the first three patients
 experiences a dose-limiting toxicity, the next cohort will be treated at the same dose level.
 The dose escalation continues until at least two patients among a cohort of three to six
 patients experience DLTs and the maximum tolerated dose (MTD) will be the dose level just
 below. If the highest planned dose was achieved without two patients experiencing DLTs, the
 MTD will be that dose level.

 The DLT is defined as grade 4 or above toxicities according to the Common Terminology
 Criteria for Adverse Events (CTCAE) version 4.03 within 4 months after stereotactic
 radiosurgery (SRS):

 Grade 4 central nervous system necrosis (life-threatening consequences; urgent intervention
 indicated) Grade 4 sensory or motor neuropathy (life-threatening consequences; urgent
 intervention indicated) Grade 4 hemorrhage (life-threatening consequences; urgent
 intervention indicated) or Grade 4 thromboembolic event (life-threatening consequences such
 as pulmonary embolism, cerebrovascular event, arterial insufficiency; hemodynamic or
 neurologic instability; urgent intervention indicated) Grade 4 hypertension (life-threatening
 consequences such as malignant hypertension, transient or permanent neurologic deficit,
 hypertensive crisis; urgent intervention indicated)

 Study treatment:

 Fractionated stereotactic radiosurgery:

 Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy
 in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose
 level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3
 fractions Three fractions will be given in one week with at least 1 day break.

 Concurrent bevacizumab:

 Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2
 weeks after the first dose of bevacizumab.
Inclusion criteria

 To be eligible for inclusion, patients must fulfill the following criteria:

 1. Patients with a histologic diagnosis of non-hematopoietic malignancy and radiographic
 evidence of measurable brain metastases (1.5~3.5 cm).

 2. The number of brain metastases receiving fractionated SRS: ≤3.

 3. No evidence of leptomeningeal metastasis on gadolinium-enhanced MRI within 30 days
 prior registration.

 4. Age ≥ 20 years.

 5. Karnofsky Performance Status ≥ 60.

 6. Life expectancy of ≥ 4 months.

 7. Women of childbearing potential and male participants must practice adequate
 contraception.

 8. Patients must be able to comply with the study protocol and follow-up schedules and
 provide study-specific informed consent.

 Exclusion criteria Patients fulfill any of the following criteria will be excluded from
 this trial

 1. Serum creatinine > 2.0 mg/dL within 30 days prior registration

 2. Contraindication to magnetic resonance (MR) imaging such as implanted metal devices or
 foreign bodies, severe claustrophobia

 3. Patients with evidence of bleeding diathesis or coagulopathy, international normalized
 ratio (INR) >1.5

 4. Patients who require the use of warfarin sodium > 1 mg

 5. Patients with active GI ulcers, GI bleeding, or active inflammatory bowel disease

 6. Patients with clinically significant cardiac disease (e.g., uncontrolled hypertension
 [blood pressure of >160/90 mmHg on medication], history of myocardial infarction or
 unstable angina within 12 months of registration), New York Heart Association (NYHA)
 Class II or greater congestive heart failure, unstable symptomatic arrhythmia
 requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial
 fibrillation or paroxysmal supraventricular tachycardia) are not eligible

 7. Patients with a history of aneurysms, cerebrovascular accident (CVA) and arteriovenous
 malformations

 8. Patients with arterial thromboembolic events, including transient ischemic attack
 (TIA), or clinically significant peripheral artery disease within 6 months of
 registration

 9. Patients with serious, non-healing wound, ulcer, or current healing fracture

 10. Patients with a history of any type of fistula (vesicovaginal, gastrointestinal, etc)
 or gastrointestinal perforation

 11. Severe, active comorbidities which, in the judgment of the investigator, would make
 the patient inappropriate for entry into this study or interfere significantly with
 the proper assessment of safety and adverse events of the protocol, or limit
 compliance with study requirements, defined as follows:

 1. Uncontrolled active infection requiring intravenous antibiotics at the time of
 registration

 2. Transmural myocardial infarction ≤ 6 months prior to registration

 3. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

 4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness
 requiring hospitalization or precluding study therapy at the time of registration

 5. Uncontrolled psychiatric disorder

 12. Will receive any other investigational agent or chemotherapy and/or target therapies
 during SRS

 13. Women of childbearing potential and male participants who are sexually active and not
 willing/able to use medically acceptable forms of contraception; this exclusion is
 necessary because the radiation treatment involved in this study may be significantly
 teratogenic